Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently.
Eagle Asset Management Inc. raised its position in Haemonetics Co. (NYSE:HAE – Free Report) by 1.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 272,526 shares of the medical instruments supplier’s stock after purchasing an additional 3,883 shares during the period. Eagle Asset Management Inc. owned […]
Haemonetics Co. (NYSE:HAE – Get Free Report) EVP Michelle L. Basil sold 12,990 shares of Haemonetics stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $88.08, for a total value of $1,144,159.20. Following the sale, the executive vice president now owns 31,257 shares of the company’s stock, […]
Haemonetics Co. (NYSE:HAE – Get Free Report) insider Stewart W. Strong sold 8,857 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $87.53, for a total value of $775,253.21. Following the transaction, the insider now directly owns 18,196 shares in the company, valued […]
Qtron Investments LLC increased its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,310 shares of the medical instruments supplier’s stock after acquiring an additional 343 shares during the quarter. Qtron […]